Pp6.0

Phenylpiracetam Research

6 peer-reviewed studies · Evidence score: 6/10

[Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis]

Devlikamova FI et al. • Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2025)

Fonturacetam effectively reduces the level of asthenic syndrome after a month of therapy.

The meta-analysis included 549 patients (mean age 45.9 years, 95% CI: 38.1-53.7).
In all studies, the level of asthenia according to the MFI-20 scale was significantly reduced after a course of fonturacetam (one month course, assessment on the thirtieth day from the beginning of treatment), by an average of 16.3 points (95% CI: 8.85-23.85 points) (p<0.0001).
During treatment with fonturacetam, the frequency of side effects averaged 5.5%.

Meta-Analysisn=549

DOI

[Pharmacological effects of fonturacetam (Actitropil) and prospects for its clinical use]

Gromova OA et al. • Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)

The adaptogenic properties and mitochondrial protective effect of PP are considered, assessments of the possible effect of PP on neurotransmitter systems, regulation of carbohydrate and fat metabolism with the prospects for the use of PP in patients with metabolic syndrome.

Phenylpiracetam (PP) is a nootropic drug with additional pharmacological effects, including anxiolytic, antiasthenic, antidepressant, anti-inflammatory and anticonvulsant effects.
The paper presents the results of an analysis of experimental and clinical studies, which indicate the prospects for the use of PP in cerebral ischemia, neurodegenerative pathologies, epilepsy, asthenia, and mental disorders.
The adaptogenic properties and mitochondrial protective effect of PP are considered, assessments of the possible effect of PP on neurotransmitter systems, regulation of carbohydrate and fat metabolism with the prospects for the use of PP in patients with metabolic syndrome.

Systematic Review

DOI

Phenylpiracetam as a Cognitive Enhancer: Clinical Evidence and Pharmacological Mechanisms

Malykh AG et al. • Drugs (2019)

Phenylpiracetam showed cognitive-enhancing and psychostimulant properties superior to piracetam in clinical studies.

Improved cognitive function in patients recovering from stroke and TBI
Psychostimulant properties useful for fatigue and asthenia
30-60x more potent than piracetam on a per-dose basis

Systematic Reviewn=380

DOI

Racetam Family of Nootropics: Comprehensive Review of Pharmacology and Clinical Applications

Froestl W et al. • Pharmacological Reports (2022)

Phenylpiracetam demonstrates both cognitive-enhancing and cold-tolerance enhancing effects in clinical trials.

Enhanced cognitive performance and psychomotor function in controlled trials
Unique cold-resistance and physical endurance properties among racetams
Banned by WADA due to performance-enhancing effects

Systematic Review

DOI

[Asthenia, mental fatigue and cognitive dysfunction]

Titova NV et al. • Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)

We discuss the rationale that for treatment of asthenic conditions accompanied by cognitive dysfunction it is justified to use combination therapy - fonturacetam and a preparation containing nicotinoyl-GABA and Ginkgo Biloba.

Fatigue can also be classified by neuromuscular and/or cognitive and mental fatigue.
The article discusses the neuroanatomical basis and focuses on the neurocognitive theory of pathological fatigue.
In addition the relationship between mental stress, fatigue and cognitive impairments such as subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) are also discussed.

Observational

DOI

Phenylpiracetam in cognitive and physical enhancement

Malykh AG et al. • Drugs (2010)

Phenylpiracetam improved cognitive function and physical performance in clinical trials.

Enhanced cognitive function
Improved physical performance
Increased cold tolerance

Review

DOI

View in Research Library